3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Papillomavirus Infections
1
Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Leukoplakia
1
Leukokeratosis, Hereditary Mucosal
1
Glioma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
2
lenvatinib
2
aldesleukin
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tivozanib
1
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
belzutifan
1
atezolizumab
1
Vaccines, Synthetic
1
Therapeutic Touch
1
Taxes
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
Radiation
1
Practice Guidelines as Topic
1
Platinum
1
Papillomavirus Vaccines
1
Nivolumab
1
Nelfinavir
1
Imiquimod
1
Hysterectomy
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Vulvar Neoplasms
×
Imiquimod
×
Clear all
NCT06686043
2024-11-13
HPV-VIM
Baylor College of Medicine
Phase 2
Recruiting
85 enrolled